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There is some evidence that there is a mismatch between what patients and health
professionals want to see researched and the research that is actually done. The
James Lind Alliance (JLA) research Priority Setting Partnerships (PSPs) were created to
address this mismatch. Between 2007 and 2014, JLA partnerships of patients, carers
and health professionals agreed on important treatment research questions
(priorities) in a range of health conditions, such as Type 1 diabetes, eczema and
stroke. We were interested in how much these JLA PSP priorities were similar to
treatments undergoing evaluation and research over the same time span. We
identified the treatments described in all the JLA PSP research priority lists and
compared these to the treatments described in a group of research studies (randomly
selected) registered publically. The priorities identified by JLA PSPs emphasised the
importance of non-drug treatment research, compared to the research actually being
done over the same time period, which mostly involved evaluations of drugs. These
findings suggest that the research community should make greater efforts to address
issues of importance to users of research, such as patients and healthcare professionals.
Abstract
Background Comparisons of treatment research priorities identified by patients and
clinicians with research actually being done by researchers are very rare. One of the
best known of these comparisons (Tallon et al. Relation between agendas of the
research community and the research consumer 355:2037–40, 2000) revealed
important mismatches in priorities in the assessment of treatments for osteoarthritis of
the knee: researchers preferenced drug trials, patients and clinicians prioritised non-
drug treatments. These findings were an important stimulus in creating the James Lind
Alliance (JLA). The JLA supports research Priority Setting Partnerships (PSPs) of patients,
carers and clinicians, who are actively involved in all aspects of the process, to develop
shared treatment research priorities. We have compared the types of treatments (inter-
ventions) prioritised for evaluation by JLA PSPs with those being studied in samples of
clinical trials being done over the same period.
Objective We used treatment research priorities generated by JLA PSPs to assess
whether, on average, treatments prioritised by patients and clinicians differ importantly
from those being studied by researchers.
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Methods We identified treatments mentioned in prioritised research questions
generated by the first 14 JLA PSPs. We compared these treatments with those assessed
in random samples of commercial and non-commercial clinical trials recruiting in the
UK over the same period, which we identified using WHO’s International Clinical Trials
Registry Platform.
Results We found marked differences between the proportions of different types of
treatments proposed by patients, carers and clinicians and those currently being
evaluated by researchers. In JLA PSPs, drugs accounted for only 18 % (23/126) of the
treatments mentioned in priorities; in registered non-commercial trials, drugs accounted
for 37 % (397/1069) of the treatments mentioned; and in registered commercial trials,
drugs accounted for 86 % (689/798) of the treatments mentioned.
Discussion Our findings confirm the mismatch first described by Tallon et al. 15 years
ago. On average, drug trials are being preferenced by researchers, and non-drug
treatments are preferred by patients, carers and clinicians. This general finding
should be reflected in more specific assessments of the extent to which research is
addressing priorities identified by the patient and clinician end users of research. It
also suggests that the research culture is slow to change in regard to how important
and relevant treatment research questions are identified and prioritised.
Keywords: Research prioritisation, James Lind Alliance, Priority setting partnerships,
Research priority setting, Mismatch in research, Treatment uncertainties, UK DUETs,
value in researchBackground
In an important report published in 2000, Tallon and colleagues showed that patients’
and clinicians’ priorities for research on the management of osteoarthritis of the knee
were not reflected in the research actually being done [1]: patients, rheumatologists,
physiotherapists and general practitioners had little enthusiasm for drug trials, yet these
constituted the vast majority of the published studies of treatments for this condition.
Patients and clinicians both said they wanted more rigorous evaluation of the effects of
physiotherapy and surgery and better assessment of the educational and coping strategies
that might help patients to manage this chronic, disabling and often painful condition. A
survey by Stewart and Oliver [2] suggests that this assessment of the mismatch between
the research needs felt by both patients and clinicians on the one hand and current re-
search agendas on the other appears to have been a rare, and possibly solitary, attempt to
audit the extent to which research agendas are meeting the needs of the patient and clin-
ician end users of research.
Three years after the paper by Tallon and colleagues, Chalmers and colleagues [3]
compared the characteristics of randomised trials funded between 1980 and 2002 by
the main non-commercial research funders in the UK. The majority of trials sup-
ported by the Medical Research Council (MRC) and the medical research charities
were funded in response to proposals made by researchers, an approach called
‘responsive funding’. The majority of trials supported by the Department of Health,
the NHS Research and Development Programme in England, the Chief Scientist
Office in Scotland and similar sources of funding in Wales and Northern Ireland
reflected priorities identified by these funders, who then called for research
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The analysis demonstrated the different consequences of these two broad
approaches. Trials funded by the MRC and research charities addressed a limited
range of treatment types (mainly drugs) and health problems (mainly cancer and
cardiovascular disease). By contrast, trials funded by the Department of Health, the
NHS Research and Development Programme and similar funders in Scotland, Wales
and Northern Ireland addressed many different types of treatments and a much
wider range of health problems [3].
The results of the studies by Tallon et al. and Stewart and Oliver, and the conse-
quences of the research funding processes described by Chalmers et al., were an im-
portant stimulus in creating the James Lind Alliance (JLA)—an initiative to establish
and develop research Priority Setting Partnerships (PSPs) of patients, carers and clini-
cians to inform treatment research agendas [4]. This initiative represented a departure
from existing processes used by research funders and was to some extent experimental.
It was viewed by many in the research community with caution and scepticism but
more positively by enough people to ensure that a wide range of partnerships were
established and built on in subsequent years.
To assess whether the mismatch reported by Tallon and colleagues [1] has been
reflected in the priorities identified by Priority Setting Partnerships over the first decade
of the James Lind Alliance, we have compared the types of treatments prioritised by
JLA PSPs with the treatments being studied in samples of clinical trials being done over
the same period.
Methods
Identification of treatment uncertainties by JLA Priority Setting Partnerships
Treatment uncertainties are identified and prioritised by James Lind Alliance Priority
Setting Partnerships (PSPs) using online and postal surveys of patients, carers and clini-
cians and the research literature. Surveys tend to ask open questions such as ‘What
questions about X would you like to see answered by research?’ so that a wide range of
people can contribute their research questions and ideas. Data are cleaned and analysed
and similar uncertainties combined, usually by an information specialist, with clinical
and patient input from the partnership steering group. These are checked to confirm
that they reflect real uncertainties. Details of this process are published online in a JLA
Guidebook [5]. An uncertainty is judged to exist when ‘no up-to-date (three years),
relevant and reliable systematic reviews of research evidence addressing the uncertainty
about the effects of treatment exist, or up-to-date relevant and reliable systematic re-
views of research evidence show that uncertainty exists’. As part of this process of
checking for genuine uncertainties, two criteria have to be met: (i) the measure of an
uncertainty used by the UK Database of Uncertainties about the Effects of Treatments
(DUETs) https://www.library.nhs.uk/duets/, which is when a reported confidence inter-
val (measure of uncertainty) in a systematic review crosses the line of no effect or line
of unity, and (ii) a clinician or person with relevant clinical knowledge confirms that
the outcome being reported as statistically significant is also clinically relevant [6].
Uncertainties that have been resolved in up-to-date systematic reviews of research
are removed from the lists of research uncertainties for prioritisation.
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A first phase of prioritisation with the community of interest (patients, carers and clini-
cians) is conducted, usually online. This consists of a list of research uncertainties open
for public vote, usually over 1 to 2 months. Information about voters, such as age and
gender, is collected and analysed to assess the share of vote across groups. This voting
process results in a shortlist of up to 30 treatment research uncertainties to be discussed
at a final priority setting workshop.
Facilitators take part in a pre-workshop briefing session, stressing the underlying princi-
ples of the discussion groups and how to deploy these. A structure for discussion and vot-
ing called ‘Nominal Group Technique’ is used to arrive at the ten most important research
uncertainties (priorities). Working in small groups, workshop participants discuss and rank
in priority order the research uncertainties in up to three rounds, with the make-up of the
small groups changing at least once. Rank scores are entered into a spreadsheet and aggre-
gated across all small groups at each stage. The next stage of discussion and voting starts
with this aggregate rank each time. After three rounds, the whole group gathers to review
the final aggregate score and agree on the final ten priorities.
Participants are reminded to bear in mind their own experiences during discussion,
as well as the voting patterns from the first prioritisation exercise. These discussions
are often emotive and challenging. Leadership from neutral facilitators helps to ensure
equitable discussion, both in terms of the amount of time that individuals use in the
discussion and the interplay of professional and lay views on the uncertainties and con-
dition(s) being considered. Discussion is typified by participants taking turns to offer
views on the treatment uncertainties being discussed and presenting rationales for
moving particular uncertainties up or down the rank order. Facilitators use the pressure
of time to keep focus on the task and seek consensus from each group before finalising
each stage of the process.
Between April 2007 and March 2013, 14 PSPs were completed using these methods:
– Asthma [7]
– Urinary incontinence [8]
– Vitiligo [9]
– Prostate cancer [10]
– Schizophrenia [11]
– Type 1 diabetes [12]
– Ear, nose and throat aspects of balance
– Life after stroke [13]
– Eczema [14]
– Tinnitus [15]
– Cleft lip and palate [16]
– Dystrophic epidermolysis bullosa [17]
– Lyme disease [18]
– Pressure ulcers
Analysing priorities from all the JLA PSPs
The priority lists from each PSP were assembled, giving a total of 149 priorities to ana-
lyse. SC and MF classified the treatments described in these priorities, using the
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two types of treatment were identified in a priority, both were entered into the analysis.
Where there were more than two treatments within a priority, these were classified as
‘mixed or complex’. When no specific treatment had been identified in the priority,
they were allocated to an ‘other’ category, for example, ‘Which treatments could reduce
weight gain in schizophrenia?’ IC was consulted when there were classification uncer-
tainties. One hundred and twenty-six treatments were mentioned in the 149 priorities
analysed. Some PSPs prioritised more than ten questions, and some prioritised ques-
tions about issues other than treatment effects.
Sampling concurrently registered clinical trials for comparison
The WHO International Clinical Trials Registry Platform was sampled for the compari-
son data. Our inclusion criteria were that studies had to be registered between January
2003 and December 2012 and that the UK was among the countries of recruitment
(our search terms are provided in additional information) Additional file 3. We re-
stricted our search to this registry as it is the most comprehensive and contains details
(and links to further information) of registered studies, mostly clinical trials. Some JLA
PSP priorities may be better addressed by other research methods that may not be cap-
tured in this registry. This may be a limitation of this approach and lead to under-
reporting of non-drug treatment research priorities.
The contents of the records of these trials were downloaded to a spreadsheet with a
script written in Python using the Beautiful Soup module (Beautiful Soup is a ‘site
scraping’ tool designed to extract data from web-based documents). The list was
checked for duplicate studies, which were removed. Our original sample size was 1703
research study records. After initial checking, 21 were removed as they did not meet in-
clusion criteria, giving a total of 1682 research studies to inspect.
A categorisation of the records into provisional ‘commercial’ and ‘non-commercial’
groups was performed by a search for keywords. This showed 52.8 % of records were
non-commercial research, and the rest (47.2 %) referred to commercially funded
studies.
SC and MF analysed the sampled trial citations together and agreed on the category
to which each study should be assigned. Often, the authors needed to check the web
links to establish exactly what the treatment was, as it was not always clear from the
study title and/or there was no plain language summary available. Additional classifica-
tion rules were developed for treatments that led to recurring classification questions
(such as herbal preparations and food additives). Samples of 879 non-commercial trials
and 803 commercial trials generated totals of 1069 and 798 mentioned treatments,
respectively.
Ethics
Ethics approval for this study was not needed as our secondary analyses had no access
to any identifiable personal data.
Results
We found marked differences between the proportions of different types of treatments
mentioned in the JLA PSP priorities and those currently being evaluated and registered
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126) of the treatments mentioned in priorities; in registered non-commercial trials,
drugs accounted for 37 % (397/1069) of the treatments mentioned; and in registered
commercial trials, drugs accounted for 86 % (689/798) of the treatments mentioned
(Table 1; Fig. 1).Discussion
Our findings mirror those reported by Tallon and colleagues [1]: there is an important
mismatch between the treatments that patients and clinicians wish to see evaluated and
the treatments being evaluated by researchers. Indeed, our analysis may have underesti-
mated the extent of the mismatch because more non-commercial than commercial tri-
als were registered at the beginning of the time period (2003–2012) over which we
aggregated data than at the end of it (data available from authors). Clearly, the research
priorities identified by the James Lind Alliance Priority Setting Partnerships cannot be
expected to be reflected in research being done at the same time, but the pattern we
have found confirms that found by Tallon et al. and is based on a much larger sample,
with data collection over a substantially longer time.
It is not a surprise that a very high proportion (86.3 %) of the registered commercial
trials concerned the evaluation of drugs. However, the very low proportion (2.6 %) of
registered commercial trials that studied the effects of the non-drug treatments rated
important by patients and clinicians is noteworthy: it suggests that few of these drug
trials can have used non-drug comparators, for example, comparing drugs with psycho-
logical therapies for treating depression.
The fact that our assessment of the research priorities of patients and clinicians has
been drawn from such a wide range of health problems is a strength. Even so, it should
not be assumed that similar findings would necessarily result from replications of simi-
lar analyses done for other health problems or for replications that are not limited to
the very highest priorities that the James Lind Alliance Priority Setting Partnerships
aim to identify.
Apart from the influence of commercial priorities, what might account for the on-
going mismatch we have shown? One obvious explanation is that the users of research
evidence apparently only very rarely contribute to setting research agendas [19], so
some research questions rated important by patients and clinicians may simply never
occur to researchers. For example, in reference to the Asthma PSP, Professor Stephen
Holgate, chair of the UK Respiratory Research Collaborative, observed that ‘Without
this coming together of patients and the research community catalysed by the JLA, the
subject of breathing exercises would never have been identified as one that received so
much enthusiastic support.’ A randomised trial to assess the effect of breathing exer-
cises was funded as a result [20]. There may also be ‘methodological disincentives’: de-
signing, running and interpreting trials of drugs will usually be methodologically
straightforward compared with evaluating the psychological or physical therapies,
service delivery and other non-drug treatments that featured so prominently among
the priorities identified by patients and clinicians.
There appear to have been few examples of researchers endeavouring to find out
what questions the patient and clinician users of research would like to see addressed
Table 1 Interventions mentioned in research priorities identified by the James Lind Alliance Priority Setting Partnerships and among registered trials, 2003–2012
Type of intervention JLA patient-clinician Priority Setting Partnerships Registered non-commercial trials Registered commercial trials
Percentages (numbers) of interventions out
of a total of 126 interventions mentioned
Percentage (numbers) of interventions out
of a total of 1069 interventions mentioned
Percentage (numbers) of interventions out
of a total of 798 interventions mentioned
Drugs, vaccines and biologicals 18.2 (23) 37.2 (397) 86.3 (689)
Radiotherapy, surgery and perioperative, devices, and
diagnostic
23.0 (29) 29.8 (332) 11.1 (89)
Education and training, service delivery, psychological therapy,
physical therapies, exercise, complementary therapies, social
care, mixed or complex, diet, other
















Fig. 1 Treatments mentioned in commercial trials, non-commercial trials and research priorities identified
by the James Lind Alliance Priority Setting Partnerships, 2003–2012
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reflected in research agendas. The research culture may be changing, as indicated in
the follow-up of JLA PSP research activity [22] and other initiatives in establishing re-
search priorities for healthcare services that fully involve patients and clinicians [23].
Follow-up has shown that some PSPs are more successful than others at sharing their
research priorities and stimulating research commissioning and proposals to address
their important questions. For example, the Sight Loss PSP used its priorities as a way
of raising the profile and diversity of research in its area. [24] Other PSPs, such as the
Life after Stroke PSP [25], have used the opportunity of a partnership to explore differ-
ent methods of engagement so that a wide range of research perspectives is gathered
and prioritised. Some of the research charities which participated in JLA PSPs have
gone on to commission research reflecting the priorities identified.
To increase the returns on their investments, we suggest that research funders assess
the extent to which the treatment research in their portfolios reflects the priorities
identified by the future users and beneficiaries of the research they fund.
A recent review of public involvement by the National Institute for Health Research
recommends that ‘relevance’ be one of the three measures of success of future public
involvement in health and social care research [26]. We suggest that research funders,
researchers and research institutions use the JLA PSP top 10 research topics, available
at http://www.jla.nihr.ac.uk/top-tens.asp and UK DUETs http://www.library.nhs.uk/
duets/, as a source of research questions to be developed and pursued. This will ensure
that they are addressing questions that reflect the interests and needs of patients, carers
and clinicians, as originally envisaged by the James Lind Alliance [27, 28].
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Our findings confirm the continuing mismatch first described 15 years ago by Tallon
et al. [1]: research on drugs is preferred by researchers, evaluation of non-drug treat-
ments is preferred by patients and clinicians. Our findings are relevant to research fun-
ders, research institutions and researchers themselves. If research is to reflect the
priorities of patients and clinicians, leadership and incentives will be needed. The
current research ‘system’ and culture is not geared to bridging the mismatch we have
documented.
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